Brokerages Set Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Target Price at $38.33

Shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) have been given an average rating of “Hold” by the five analysts that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $38.3333.

PHAR has been the topic of several recent analyst reports. Weiss Ratings lowered Pharming Group from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Canaccord Genuity Group initiated coverage on Pharming Group in a research report on Friday, April 10th. They issued a “buy” rating and a $37.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $37.00 price objective on shares of Pharming Group in a research report on Tuesday, March 24th. Oppenheimer reiterated an “outperform” rating and issued a $41.00 price objective (down from $42.00) on shares of Pharming Group in a research report on Friday, March 13th. Finally, Zacks Research upgraded Pharming Group from a “strong sell” rating to a “hold” rating in a research report on Friday, April 10th.

Pharming Group Price Performance

Shares of PHAR stock opened at $13.89 on Wednesday. The stock’s fifty day simple moving average is $13.71 and its 200 day simple moving average is $15.85. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.63 and a quick ratio of 2.06. The firm has a market cap of $980.91 million, a price-to-earnings ratio of 86.82 and a beta of -0.04. Pharming Group has a one year low of $9.54 and a one year high of $21.34.

Pharming Group (NASDAQ:PHAR) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.12). The company had revenue of $72.45 million during the quarter, compared to analyst estimates of $92.06 million. Pharming Group had a net margin of 3.30% and a return on equity of 4.64%. On average, analysts expect that Pharming Group will post 0.6 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pharming Group

Institutional investors have recently bought and sold shares of the business. EverSource Wealth Advisors LLC bought a new position in Pharming Group in the 2nd quarter valued at $32,000. SmartHarvest Portfolios LLC bought a new position in Pharming Group in the 4th quarter valued at $224,000. Millennium Management LLC bought a new position in Pharming Group in the 4th quarter valued at $360,000. Finally, NewEdge Advisors LLC raised its position in Pharming Group by 11,310.3% in the 4th quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after purchasing an additional 28,615 shares during the last quarter. Institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.